Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 18, 2006

Malaria Discovery Collaboration Agreement Expanded

  • Medicines for Malaria Venture (MMV), Genzyme, and the Broad Institute of MIT and Harvard expanded their collaboration to discover and advance new therapeutic candidates for malaria. The alliance will build on work begun earlier this year to extend a drug discovery program focused on identifying compounds that offer a completely new approach to treating malaria.

    In addition to co-funding and co-managing this effort with Genzyme and the Broad Institute, MMV will also work with the two partners to secure additional resources to scale-up the program further. Currently, there are four early discovery projects in this portfolio, the collaborators inform. All intellectual property developed under this collaboration will be made available to MMV on a royalty-free basis for use in developing and distributing new drugs for the treatment of malaria.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »